Neurocrine Biosciences Inc vs Quantum Computing Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Quantum Computing Inc trades at $8.29 (market cap $1.79B). The key difference: Neurocrine Biosciences Inc is far larger — about 9.7× Quantum Computing Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | QUBT | |
|---|---|---|
Market Cap | $17.40B | $1.79B |
Sector | Health | Technology |
52-Week High | $180.55 | $24.62 |
52-Week Low | $123.10 | $6.31 |
Enterprise Value | $16.49B | $803.83M |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →